• darkblurbg

    TARGETING THE UNDERLYING

    CAUSES OF DIABETES

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Both Diamyd® and Remygen® are at an exciting stage with an opportunity to reach the market faster than would otherwise be expected for drugs at the same development phase.

Ulf Hannelius
President and CEO, Diamyd Medical AB

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)


Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The effifficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the PhaseIIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes will be evaluated for the first time in 2018.